Appendix

[1] B. Zinman et al., “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes,” N. Engl. J. Med., vol. 373, no. 22, pp. 2117–28, 2015, doi: 10 ... ................
................